ID   HL-60/CDDP
AC   CVCL_C3M3
DR   Wikidata; Q116049332
RX   DOI=10.7546/CRABS.2022.07.13;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0002 ! HL-60
SX   Female
AG   36Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 29-06-23; Version: 3
//
RX   DOI=10.7546/CRABS.2022.07.13;
RA   Mihaylova R., Zhelezova I., Simeonova R., Momekov G.;
RT   "Establishment and biochemical characterization of a multidrug-
RT   resistant promyelocytic leukemia cell line HL-60/CDDP.";
RL   C. R. Acad. Bulg. Sci. 75:1045-1052(2022).
//